Human Siglec-2/CD22 Protein
Catalog No: CD22-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human Siglec-2/CD22 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Asp20-Arg687 (UniProt accession: P20273-1).
Product Details
- Molecular Aliases
- CD22 molecule; CD22; Siglec-2; B-cell receptor CD22; BL-CAM; SIGLEC2; SIGLEC2FLJ22814
- Protein Length
- Asp20-Arg687
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 101.9 kDa. Due to glycosylation, the protein migrates to 120-130 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human Siglec-2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Human Siglec-2, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-Siglec-2 Antibody, hFc Tag with the EC50 of 14.9ng/ml determined by ELISA (QC Test).
Background
CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.
References
- Kato J, Robert T. O'Donnell, Abuhay M, et al. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma[J]. OncoImmunology, 2012, 1(9):7.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.